Visirna Therapeutics, a China-based company with a global vision, opened an R&D center in Suzhou Dushu Lake Sci-Edu Innovation District in SIP on Mar 6, aiming to accelerate research and development of oligonucleotide therapeutics.
Visirna was founded in 2022 in a strategic partnership with Arrowhead Pharmaceuticals. It is currently working on three first-in-class late clinical-stage siRNA candidates for the treatment of cardiovascular and metabolic diseases.
The R&D center is equipped with automated oligonucleotide synthesis and purification platforms and other advanced equipment to help strengthen Visirna’s existing clinical portfolio.
March 6, 2024
